Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 381


Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.

Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, Wheeler DL.

Clin Cancer Res. 2018 Dec 1;24(23):6099. doi: 10.1158/1078-0432.CCR-18-3194. No abstract available.


Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma.

Wang J, Mirzapoiazova T, Carol Tan YH, Pang KM, Pozhitkov A, Wang Y, Wang Y, Mambetsariev B, Wang E, Nasser MW, Batra SK, Raz D, Reckamp K, Kulkarni P, Zheng Y, Salgia R.

Cancer Biol Ther. 2018 Oct 12:1-10. doi: 10.1080/15384047.2018.1472193. [Epub ahead of print]


Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade.

Gong J, Hendifar A, Tuli R, Chuang J, Cho M, Chung V, Li D, Salgia R.

Clin Transl Med. 2018 Oct 8;7(1):32. doi: 10.1186/s40169-018-0210-9. Review.


Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly.

Shinde A, Li R, Kim J, Salgia R, Hurria A, Amini A.

Semin Oncol. 2018 Aug;45(4):210-219. doi: 10.1053/j.seminoncol.2018.06.002. Epub 2018 Jul 1. Review.


Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM.

J Thorac Oncol. 2018 Nov;13(11):1655-1667. doi: 10.1016/j.jtho.2018.08.2036. Epub 2018 Sep 25.


2'-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells.

Nagaprashantha LD, Singhal J, Chikara S, Gugiu G, Horne D, Awasthi S, Salgia R, Singhal SS.

J Proteomics. 2018 Sep 21. pii: S1874-3919(18)30346-4. doi: 10.1016/j.jprot.2018.09.005. [Epub ahead of print]


Metastasis of breast tumor cells to brain is suppressed by targeting RLIP alone and in combination with 2'-Hydroxyflavanone.

Singhal J, Singhal P, Horne D, Salgia R, Awasthi S, Singhal SS.

Cancer Lett. 2018 Dec 1;438:144-153. doi: 10.1016/j.canlet.2018.09.015. Epub 2018 Sep 15.


2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76.

Singhal J, Chikara S, Horne D, Salgia R, Awasthi S, Singhal SS.

Mol Carcinog. 2018 Dec;57(12):1751-1762. doi: 10.1002/mc.22894. Epub 2018 Sep 19.


Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer.

Hill A, Gong J, Wilczynski S, Mirza R, Erhunmwunsee L, Salgia R.

J Oncol Pract. 2018 Sep;14(9):569-571. doi: 10.1200/JOP.18.00127. Epub 2018 Jul 25. No abstract available.


Heuristic value-based framework for lung cancer decision-making.

Mambetsariev I, Pharaon R, Nam A, Knopf K, Djulbegovic B, Villaflor VM, Vokes EE, Salgia R.

Oncotarget. 2018 Jul 6;9(52):29877-29891. doi: 10.18632/oncotarget.25643. eCollection 2018 Jul 6.


A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.

Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR.

Cancer Chemother Pharmacol. 2018 Aug;82(2):309-317. doi: 10.1007/s00280-018-3619-3. Epub 2018 Jun 9.


Graft-versus-host disease of the central nervous system after liver transplantation: A rare complication.

Pahari H, Nagai S, Skorupski S, Salgia R.

Am J Transplant. 2018 Oct;18(10):2591-2594. doi: 10.1111/ajt.14981. Epub 2018 Jul 20.


Chances of Renal Recovery or Liver Transplantation After Hospitalization for Alcoholic Liver Disease Requiring Dialysis.

Lenhart A, Hussain S, Salgia R.

Dig Dis Sci. 2018 Oct;63(10):2800-2809. doi: 10.1007/s10620-018-5170-9. Epub 2018 Jun 22.


Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target.

Salgia R, Jolly MK, Dorff T, Lau C, Weninger K, Orban J, Kulkarni P.

J Clin Med. 2018 Jun 17;7(6). pii: E156. doi: 10.3390/jcm7060156. Review.


Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models.

Salgia R, Mambetsariev I, Hewelt B, Achuthan S, Li H, Poroyko V, Wang Y, Sattler M.

Oncotarget. 2018 May 25;9(40):26226-26242. doi: 10.18632/oncotarget.25360. eCollection 2018 May 25. Review.


Managing Patients With Relapsed Small-Cell Lung Cancer.

Gong J, Salgia R.

J Oncol Pract. 2018 Jun;14(6):359-366. doi: 10.1200/JOP.18.00204.


Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients.

Poroyko V, Mirzapoiazova T, Nam A, Mambetsariev I, Mambetsariev B, Wu X, Husain A, Vokes EE, Wheeler DL, Salgia R.

Oncotarget. 2018 Apr 13;9(28):19793-19806. doi: 10.18632/oncotarget.24857. eCollection 2018 Apr 13.


Untying the gordion knot of targeting MET in cancer.

Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D.

Cancer Treat Rev. 2018 May;66:95-103. doi: 10.1016/j.ctrv.2018.04.008. Epub 2018 Apr 26. Review.


2'-Hydroxyflavanone effectively targets RLIP76-mediated drug transport and regulates critical signaling networks in breast cancer.

Nagaprashantha LD, Singhal J, Li H, Warden C, Liu X, Horne D, Awasthi S, Salgia R, Singhal SS.

Oncotarget. 2018 Apr 6;9(26):18053-18068. doi: 10.18632/oncotarget.24720. eCollection 2018 Apr 6.


Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.

Pal SK, Bergerot P, Dizman N, Bergerot C, Adashek J, Madison R, Chung JH, Ali SM, Jones JO, Salgia R.

Eur Urol. 2018 Jul;74(1):124-128. doi: 10.1016/j.eururo.2018.03.032. No abstract available.


Value-based genomics.

Gong J, Pan K, Fakih M, Pal S, Salgia R.

Oncotarget. 2018 Jan 30;9(21):15792-15815. doi: 10.18632/oncotarget.24353. eCollection 2018 Mar 20. Review.


Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy.

Mambetsariev I, Vora L, Yu KW, Salgia R.

BMC Cancer. 2018 Mar 21;18(1):314. doi: 10.1186/s12885-018-4222-z.


B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies.

Xiao G, Chan LN, Klemm L, Braas D, Chen Z, Geng H, Zhang QC, Aghajanirefah A, Cosgun KN, Sadras T, Lee J, Mirzapoiazova T, Salgia R, Ernst T, Hochhaus A, Jumaa H, Jiang X, Weinstock DM, Graeber TG, Müschen M.

Cell. 2018 Apr 5;173(2):470-484.e18. doi: 10.1016/j.cell.2018.02.048. Epub 2018 Mar 15.


Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance).

Urbanic JJ, Wang X, Bogart JA, Stinchcombe TE, Hodgson L, Schild SE, Bazhenova L, Hahn O, Salgia R, Vokes EE.

Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):177-185. doi: 10.1016/j.ijrobp.2018.01.046. Epub 2018 Jan 31.


The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer.

Salgia R, Kulkarni P.

Trends Cancer. 2018 Feb;4(2):110-118. doi: 10.1016/j.trecan.2018.01.001. Epub 2018 Feb 3. Review.


The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.

Amanam I, Gupta R, Mambetsariev I, Salgia R.

Future Oncol. 2018 Aug;14(19):1897-1908. doi: 10.2217/fon-2017-0545. Epub 2018 Feb 16.


EphB4: A promising target for upper aerodigestive malignancies.

Salgia R, Kulkarni P, Gill PS.

Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):128-137. doi: 10.1016/j.bbcan.2018.01.003. Epub 2018 Jan 31. Review.


Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.

Gong J, Chehrazi-Raffle A, Reddi S, Salgia R.

J Immunother Cancer. 2018 Jan 23;6(1):8. doi: 10.1186/s40425-018-0316-z. Review.


Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.

Kanteti R, Mirzapoiazova T, Riehm JJ, Dhanasingh I, Mambetsariev B, Wang J, Kulkarni P, Kaushik G, Seshacharyulu P, Ponnusamy MP, Kindler HL, Nasser MW, Batra SK, Salgia R.

Cancer Biol Ther. 2018 Apr 3;19(4):316-327. doi: 10.1080/15384047.2017.1416937. Epub 2018 Feb 22.


Hepatocellular Carcinoma: A Decade of Hospitalizations and Financial Burden in the United States.

Jinjuvadia R, Salami A, Lenhart A, Jinjuvadia K, Liangpunsakul S, Salgia R.

Am J Med Sci. 2017 Oct;354(4):362-369. doi: 10.1016/j.amjms.2017.05.016. Epub 2017 Jun 1.


State-of-the-art considerations in small cell lung cancer brain metastases.

Lukas RV, Gondi V, Kamson DO, Kumthekar P, Salgia R.

Oncotarget. 2017 Jul 18;8(41):71223-71233. doi: 10.18632/oncotarget.19333. eCollection 2017 Sep 19. Review.


Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming.

Bhanot H, Weisberg EL, Reddy MM, Nonami A, Neuberg D, Stone RM, Podar K, Salgia R, Griffin JD, Sattler M.

Oncotarget. 2017 Jun 28;8(40):67639-67650. doi: 10.18632/oncotarget.18797. eCollection 2017 Sep 15.


Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience.

Yuan Y, Yost SE, Yim J, Yuan YC, Solomon NM, Mambetsariev I, Pal S, Frankel P, Salgia R, Neuhausen SL, Mortimer J.

Oncotarget. 2017 Sep 22;8(37):62817. doi: 10.18632/oncotarget.20632. eCollection 2017 Sep 22.


A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.

Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G Jr, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ.

BMC Cancer. 2017 Sep 12;17(1):646. doi: 10.1186/s12885-017-3641-6.


Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.

Tan YC, Mirzapoiazova T, Won BM, Zhu L, Srivastava MK, Vokes EE, Husain AN, Batra SK, Sharma S, Salgia R.

Sci Rep. 2017 Aug 23;7(1):9192. doi: 10.1038/s41598-017-09078-4.


Outcome of liver transplantation in patients with prior bariatric surgery.

Safwan M, Collins KM, Abouljoud MS, Salgia R.

Liver Transpl. 2017 Nov;23(11):1415-1421. doi: 10.1002/lt.24832.


Empowering survivors after colorectal and lung cancer treatment: Pilot study of a Self-Management Survivorship Care Planning intervention.

Reb A, Ruel N, Fakih M, Lai L, Salgia R, Ferrell B, Sampath S, Kim JY, Raz DJ, Sun V.

Eur J Oncol Nurs. 2017 Aug;29:125-134. doi: 10.1016/j.ejon.2017.06.003. Epub 2017 Jun 19.


Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms.

Wood K, Byron E, Janisch L, Salgia R, Sharma MR.

Am J Clin Oncol. 2018 Oct;41(10):963-966. doi: 10.1097/COC.0000000000000400.


Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.

Jen J, Lin LL, Lo FY, Chen HT, Liao SY, Tang YA, Su WC, Salgia R, Hsu CL, Huang HC, Juan HF, Wang YC.

Oncogene. 2017 Sep 7;36(36):5219. doi: 10.1038/onc.2017.203. Epub 2017 Jun 19.


Canonical and alternative transcript expression of PAX6 and CXCR4 in pancreatic cancer.

Little EC, Kubic JD, Salgia R, Grippo PJ, Lang D.

Oncol Lett. 2017 Jun;13(6):4027-4034. doi: 10.3892/ol.2017.5956. Epub 2017 Mar 29.


Value-Based Medicine and Integration of Tumor Biology.

Brooks GA, Bosserman LD, Mambetsariev I, Salgia R.

Am Soc Clin Oncol Educ Book. 2017;37:833-840. doi: 10.14694/EDBK_175519. Review.


Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma.

Zhang K, Wang J, Tong TR, Wu X, Nelson R, Yuan YC, Reno T, Liu Z, Yun X, Kim JY, Salgia R, Raz DJ.

Int J Cancer. 2017 Aug 15;141(4):766-777. doi: 10.1002/ijc.30769. Epub 2017 May 31.


The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.

Mok TSK, Crino L, Felip E, Salgia R, De Pas T, Tan DSW, Chow LQM.

Cancer Treat Rev. 2017 Apr;55:181-189. doi: 10.1016/j.ctrv.2017.03.006. Epub 2017 Mar 30. Review.


Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway.

Ando K, Shah AK, Sachdev V, Kleinstiver BP, Taylor-Parker J, Welch MM, Hu Y, Salgia R, White FM, Parvin JD, Ozonoff A, Rameh LE, Joung JK, Bharti AK.

Oncotarget. 2017 Jul 4;8(27):43733-43751. doi: 10.18632/oncotarget.16376.


MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.

Salgia R.

Mol Cancer Ther. 2017 Apr;16(4):555-565. doi: 10.1158/1535-7163.MCT-16-0472. Review.


Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.

Jen J, Lin LL, Lo FY, Chen HT, Liao SY, Tang YA, Su WC, Salgia R, Hsu CL, Huang HC, Juan HF, Wang YC.

Oncogene. 2017 Aug;36(31):4526. doi: 10.1038/onc.2017.77. Epub 2017 Apr 3.


Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.

Salgia R, Weaver RW, McCleod M, Stille JR, Yan SB, Roberson S, Polzer J, Flynt A, Raddad E, Peek VL, Wijayawardana SR, Um SL, Gross S, Connelly MC, Morano C, Repollet M, Sanders R, Baeten K, D'Haese D, Spigel DR.

Invest New Drugs. 2017 Jun;35(3):334-344. doi: 10.1007/s10637-017-0446-z. Epub 2017 Mar 15.


A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.

Salgia R, Stille JR, Weaver RW, McCleod M, Hamid O, Polzer J, Roberson S, Flynt A, Spigel DR.

Lung Cancer. 2017 Mar;105:7-13. doi: 10.1016/j.lungcan.2016.12.020. Epub 2016 Dec 31.


Predictors of Waitlist Mortality in Portopulmonary Hypertension.

DuBrock HM, Goldberg DS, Sussman NL, Bartolome SD, Kadry Z, Salgia RJ, Mulligan DC, Kremers WK, Kawut SM, Krowka MJ, Channick RN.

Transplantation. 2017 Jul;101(7):1609-1615. doi: 10.1097/TP.0000000000001666.


Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience.

Gong J, Cho M, Sy M, Salgia R, Fakih M.

Oncotarget. 2017 Jun 27;8(26):42198-42213. doi: 10.18632/oncotarget.15030.

Supplemental Content

Loading ...
Support Center